Literature DB >> 10436139

Platelet PlA2 polymorphism and thromboembolic events: from inherited risk to pharmacogenetics.

P J Goldschmidt-Clermont1, C M Roos, G E Cooke.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10436139     DOI： 10.1023/a:1008954916972

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  115 in total

1.  Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial.

Authors:  S P Schulman; P J Goldschmidt-Clermont; E J Topol; R M Califf; F I Navetta; J T Willerson; N C Chandra; A D Guerci; J J Ferguson; R A Harrington; A M Lincoff; S J Yakubov; P F Bray; R D Bahr; C L Wolfe; P G Yock; H V Anderson; T W Nygaard; S J Mason; M B Effron; A Fatterpacker; S Raskin; J Smith; L Brashears; P Gottdiener; C du Mee; M M Kitt; G Gerstenblith
Journal:  Circulation       Date:  1996-11-01       Impact factor: 29.690

Review 2.  GPIIb/IIIa antagonists: pathophysiologic and therapeutic insights from studies of c7E3 Fab.

Authors:  B S Coller
Journal:  Thromb Haemost       Date:  1997-07       Impact factor: 5.249

3.  Selective inhibition of integrin function by antibodies specific for ligand-occupied receptor conformers.

Authors:  A L Frelinger; I Cohen; E F Plow; M A Smith; J Roberts; S C Lam; M H Ginsberg
Journal:  J Biol Chem       Date:  1990-04-15       Impact factor: 5.157

4.  A human beta-actin expression vector system directs high-level accumulation of antisense transcripts.

Authors:  P Gunning; J Leavitt; G Muscat; S Y Ng; L Kedes
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

5.  Parental history is an independent risk factor for coronary artery disease: the Framingham Study.

Authors:  R H Myers; D K Kiely; L A Cupples; W B Kannel
Journal:  Am Heart J       Date:  1990-10       Impact factor: 4.749

6.  Dynamic actin structures stabilized by profilin.

Authors:  T Finkel; J A Theriot; K R Dise; G F Tomaselli; P J Goldschmidt-Clermont
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

7.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

8.  A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

Authors:  M B Leon; D S Baim; J J Popma; P C Gordon; D E Cutlip; K K Ho; A Giambartolomei; D J Diver; D M Lasorda; D O Williams; S J Pocock; R E Kuntz
Journal:  N Engl J Med       Date:  1998-12-03       Impact factor: 91.245

9.  Platelet GP IIIa PlA and GP Ib variable number tandem repeat polymorphisms and markers of platelet activation in acute stroke.

Authors:  A M Carter; A J Catto; J M Bamford; P J Grant
Journal:  Arterioscler Thromb Vasc Biol       Date:  1998-07       Impact factor: 8.311

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245
View more
  1 in total

1.  The GPIIIA PlA2 polymorphism is associated with an increased risk of cardiovascular adverse events.

Authors:  Gennaro Galasso; Gaetano Santulli; Federico Piscione; Roberta De Rosa; Valentina Trimarco; Raffaele Piccolo; Salvatore Cassese; Guido Iaccarino; Bruno Trimarco; Massimo Chiariello
Journal:  BMC Cardiovasc Disord       Date:  2010-09-16       Impact factor: 2.298
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.